Pfizer said in a statement the proceeds from the sale would be used to buy back stock in addition to the previously announced repurchase program of about $5 billion planned for 2011.
The New Jersey-based Capsugel had about $750 million in revenue and manufactured more than 180 billion hard capsules in 2010.
"The transaction is an endorsement of Capsugel's consistent success to date and its potential for future growth with KKR, a firm with deep industry expertise and a long history of partnering with market-leading businesses to take them to the next level," said Guido Driesen, president and general manager of Capsugel, in the statement.
Pfizer, based in New York, said the transaction was expected to close during the third quarter, subject to approval from US, European Union and other regulators.
Assuming the sale is completed, Pfizer lowered its 2011 revenue forecast to a range of $65.2-67.2 billion from previous guidance of $66.0-68.0 billion.
The revenue target range also was revised lower, to $62.2-64.7 billion from $63.0-65.5 billion. The company's other financial forecasts were left unchanged.
Source: AFP
For more than two decades, I-Net Bridge has been one of South Africa’s preferred electronic providers of innovative solutions, data of the highest calibre, reliable platforms and excellent supporting systems. Our products include workstations, web applications and data feeds packaged with in-depth news and powerful analytical tools empowering clients to make meaningful decisions.
We pride ourselves on our wide variety of in-house skills, encompassing multiple platforms and applications. These skills enable us to not only function as a first class facility, but also design, implement and support all our client needs at a level that confirms I-Net Bridge a leader in its field.
Go to: http://www.inet.co.za
